EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Mangiferin and norathyriol acting on Alzheimer’s disease biomarkers: acetylcholinesterase, β-secretase (BACE-1), and amyloid β-peptide

Tiago Bento de Oliveira, Ana Claudia Beneton Galeriani, José R Rodrigues de Souza, Daniel F Kawano, Maria Teresa Salles Trevisan, Wanda P Almeida

Journal of Pharmacy and Pharmacology · 2025-10-30 · 77 (11) · 1513-1522

DOI: 10.1093/jpp/rgaf055 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives Mangiferin, a chemical constituent of Mangifera indica, has been the subject of extensive investigation due to its diverse biological activities, as detailed in numerous scientific studies. Its aglycone, norathyriol, has similarly garnered attention from researchers. In furtherance of our ongoing research goals, this article presents an evaluation of these compounds in relation to biomarkers associated with Alzheimer’s disease. Methods The inhibition of acetylcholinesterase (AChE) and β-secretase (BACE-1), as well as the aggregation of the amyloid beta (Aβ)42 peptide, was assessed using Ellman’s colourimetric method, fluorescence resonance energy transfer (FRET), and thioflavin-T fluorescence emission, respectively. Key findings Mangiferin exhibited no inhibitory effect on AChE, whereas norathyriol demonstrated an inhibitory concentration (IC50) of 6.23 μM. Molecular docking revealed that the mangiferin-AChE and mangiferin-BACE-1 complexes did not interact with sites related to enzyme activity. In contrast, norathyriol showed favourable interactions with Asp72 at the peripheral site of AChE and formed significant interactions with BACE-1 through hydrogen bonds, as suggested by molecular docking. The IC50 of norathyriol for BACE-1 inhibition was found to be 9.75 μM. The reduction in Aβ42 aggregation by norathyriol was only 28%. Conclusion We conclude that norathyriol is a promising prototype for drug development aimed at treating Alzheimer’s disease.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →